Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 4/20 | 0.69 |
| ▸ | JAK3 | P52333 | 2/20 | 0.69 |
| ▸ | EGFR | P00533 | 15/20 | 0.68 |
| ▸ | ITK | Q08881 | 5/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21338050 | 0.92 | BTK (0.68) | BTKJAK3EGFRITK | |
| SCHEMBL12519542 | 0.92 | EGFR (0.79) | BTKJAK3EGFRITK | |
| SCHEMBL21338057 | 0.91 | EGFR (0.72) | BTKJAK3EGFRITK | |
| SCHEMBL12519536 | 0.90 | EGFR (0.82) | BTKJAK3EGFRITK | |
| SCHEMBL21338051 | 0.89 | ITK (0.68) | BTKJAK3EGFRITK | |
| SCHEMBL30672892 | 0.88 | EGFR (0.65) | BTKJAK3EGFRITK | |
| SCHEMBL16370821 | 0.88 | EGFR (0.65) | BTKJAK3EGFRITK | |
| SCHEMBL16706331 | 0.86 | BTK (0.62) | BTKJAK3EGFRITK | |
| SCHEMBL16706325 | 0.86 | BTK (0.61) | BTKJAK3EGFRITK | |
| SCHEMBL16372156 | 0.86 | EGFR (0.81) | BTKJAK3EGFRITK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210309642-A1 | Process for Manufacture of (S)-N-(3-((2-((4-((1-acetylpyrrolidin-3-yl)(methyl)amino)phenyl)amino)-5-methoxypyrimidin-4-yl)oxy)phenyl)acrylamide, and Formulations Thereof | ACEA Therapeutics, Inc. (US) | 2021-10-07 | — | — | US | disclosed |
| WO-2020029156-A1 | PROCESS FOR MANUFACTURE OF (S)-N-(3-((2-((4-((1-ACETYLPYRROLIDIN-3-YL)(METHYL)AMINO)PHENYL)AMINO)-5-METHOXYPYRIMIDIN-4-YL)OXY) PHENYL)ACRYLAMIDE, AND FORMULATIONS THEREOF | ACEA Therapeutics, Inc. (US) | 2020-02-13 | — | — | WO | disclosed |
| EP-3019496-B1 | PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS | ACEA THERAPEUTICS INC (US) | 2019-09-11 | — | — | EP | disclosed |
| US-9920074-B2 | Heterocyclic compounds and uses thereof | ACEA BIOSCIENCES INC. (US) | 2018-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210309642-A1 | Process for Manufacture of (S)-N-(3-((2-((4-((1-acetylpyrrolidin-3-yl)(methyl)amino)phenyl)amino)-5-methoxypyrimidin-4-yl)oxy)phenyl)acrylamide, and Formulations Thereof | BMX, ITK, BLK | BTK 4/4885JAK3 8/4885EGFR 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.